BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-10
211 industry Phase 2/3 trial readout(s) and 61 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-10 est. | P3 | NS Pharma, Inc. | NCT04768062 Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) | Duchenne Muscular Dystrophy | active not recruiting | 74 |
| 2025-10 est. | P1/P2 | Telios Pharma, Inc. | NCT05280509 Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | Myelofibrosis; Primary Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis | recruiting | 70 |
| 2025-10 est. | P3 | Shanghai Miracogen Inc. | NCT05754853 A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Ca | Advanced or Metastatic Urothelium Cancer | recruiting | 290 |
| 2025-10 est. | P1/P2 | Guangzhou Excelmab Inc. | NCT06021678 Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma | CD20-positive Non-Hodgkin Lymphoma | recruiting | 415 |
| 2025-10 est. | P2 | Tasly Pharmaceutical Group Co., Ltd | NCT06058546 Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis | Plaque Psoriasis | unknown | 180 |
| 2025-10 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06308406 A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | Recurrent Ovarian Cancer | unknown | 54 |
| 2025-10 est. | P2 | Areteia Therapeutics | NCT06533553 A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD | Chronic Obstructive Pulmonary Disease | active not recruiting | 30 |
| 2025-10 est. | P3 | Tonghua Dongbao Pharmaceutical Co.,Ltd | NCT06559722 A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes | Type 2 Diabetes | unknown | 510 |
| 2025-10 est. | P2 | Aurion Biotech | NCT06630169 Study of Cryopreserved AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction | Corneal Edema | active not recruiting | 25 |
| 2025-10 est. | P2 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | NCT06854445 Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma | Diffuse Large Cell B-lymphoma | recruiting | 55 |
| 2025-10 est. | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT06940700 Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma | Asthma | not yet recruiting | 60 |
| 2025-10 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT07011186 A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies | Myeloid Malignancy | recruiting | 138 |
| 2025-10-01 | P3 | Hoffmann-La Roche | NCT03456063 A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell | Non-Small-Cell Lung | completed | 453 |
| 2025-10-01 est. | P2 | CellSight Technologies, Inc. | NCT03684655 Imaging Immune Activation in HIV by PET-MR | HIV Infections | unknown | 30 |
| 2025-10-01 | P2 | Hi-Q Marine Biotech International, Ltd. | NCT04597476 A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck | Squamous Cell Carcinomas of the Head and Neck | completed | 69 |
| 2025-10-01 | P2 | Bioverativ, a Sanofi company | NCT04658472 Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | completed | 98 |
| 2025-10-01 est. | P2 | Anterogen Co., Ltd. | NCT05157958 Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa | Dystrophic Epidermolysis Bullosa | unknown | 6 |
| 2025-10-01 est. | P2 | Virogin Biotech Canada Ltd | NCT05223816 An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With N | Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma | unknown | 97 |
| 2025-10-01 | P3 | Dexa Medica Group | NCT05248802 DLBS2411 Treatment For Functional Dyspepsia | Functional Dyspepsia | completed | 106 |
| 2025-10-01 | P3 | Harmony Biosciences Management, Inc. HRMY | NCT05458128 A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia | Idiopathic Hypersomnia; Excessive Daytime Sleepiness | completed | 119 |
| 2025-10-01 | P2 | Eli Lilly and Company LLY | NCT05936151 A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight or Obesity; CKD; Type 2 Diabetes | completed | 146 |
| 2025-10-01 | P2 | Sanofi SNY | NCT06015308 A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo | Dermatitis Atopic | completed | 224 |
| 2025-10-01 | P3 | Bristol-Myers Squibb BMY | NCT06045689 A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants | Myelodysplastic Syndromes | active not recruiting | 106 |
| 2025-10-01 | P2 | GlaxoSmithKline | NCT06317285 A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | terminated | 158 |
| 2025-10-01 | P3 | Novo Nordisk A/S NVO | NCT06323174 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | Type 2 Diabetes | completed | 189 |
| 2025-10-01 | P2 | Rallybio RLYB | NCT06435845 Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization | Fetal and Neonatal Alloimmune Thrombocytopenia | terminated | 1 |
| 2025-10-01 | P2 | Novo Nordisk A/S NVO | NCT06542874 A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes | Type 2 Diabetes (T2D) | completed | 448 |
| 2025-10-01 est. | P2 | Zhejiang Kanova Biopharmaceutical Co., LTD | NCT07054736 Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | not yet recruiting | 120 |
| 2025-10-02 | P1/P2 | Ryvu Therapeutics SA | NCT05052255 RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors | Advanced Solid Tumor | terminated | 66 |
| 2025-10-02 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT05115838 Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043) | Human Immunodeficiency Virus; HIV | withdrawn | |
| 2025-10-02 | P3 | Sanofi SNY | NCT05222906 Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 | Gaucher's Disease Type III | active not recruiting | 43 |
| 2025-10-02 | P3 | AstraZeneca AZN | NCT05771480 Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | Biliary Tract Cancer | active not recruiting | 142 |
| 2025-10-02 | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06682000 Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension | Hypertension; Essential Hypertension | completed | 192 |
| 2025-10-03 | P2 | Hope Biosciences Research Foundation | NCT04995081 Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) | Parkinson Disease | completed | 60 |
| 2025-10-03 | P2 | Pfizer PFE | NCT05429372 Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy | Muscular Dystrophy, Duchenne | terminated | 10 |
| 2025-10-03 | P2 | Aadi Bioscience, Inc. | NCT05997056 Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received | Neuroendocrine Tumors; NET; Pancreatic Neuroendocrine Tumor; Gastrointestinal Neuroendocrine Tumor; | completed | 12 |
| 2025-10-03 | P1/P2 | Entos Pharmaceuticals Inc. | NCT06436911 To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA | COVID-19 | completed | 46 |
| 2025-10-03 | P2 | Allay Therapeutics, Inc. | NCT06799845 Phase 2B Study Assessing Pain Relief After Replacement of the Knee | Total Knee Arthroplasty (Postoperative Pain) | completed | 226 |
| 2025-10-03 | P3 | Dexa Medica Group | NCT07420491 The Efficacy and Safety of Reconyl in Acute Cough Treatment | Cough | completed | 144 |
| 2025-10-05 | P2 | AM-Pharma | NCT06168799 Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery | Open Heart Surgery | completed | 271 |
| 2025-10-06 | P3 | AbbVie ABBV | NCT04578756 Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, | Schizophrenia; Bipolar I Disorder; Autism Spectrum Disorder (ASD) | completed | 310 |
| 2025-10-06 | P1/P2 | Artiva Biotherapeutics, Inc. ARTV | NCT04673617 AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Non Hodgkin Lymphoma | completed | 45 |
| 2025-10-06 | P3 | AstraZeneca AZN | NCT05450692 A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prio | Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | 594 |
| 2025-10-06 | P1/P2 | Integro Theranostics | NCT05900986 LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer | Breast Cancer; DCIS; Invasive Duct Carcinoma of Breast | completed | 22 |
| 2025-10-06 | P2 | Transcend Therapeutics | NCT06237426 An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD | Post Traumatic Stress Disorder | completed | 44 |
| 2025-10-06 | P2 | Amgen AMGN | NCT06660173 A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes Mellitus (T2DM) | active not recruiting | 409 |
| 2025-10-06 | P2 | Vanda Pharmaceuticals VNDA | NCT06804603 A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use | Obesity | completed | 124 |
| 2025-10-07 | P3 | Actelion | NCT04273945 Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | active not recruiting | 935 |
| 2025-10-07 | P3 | Alexion Pharmaceuticals, Inc. | NCT05746559 ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | Chronic Kidney Disease; CKD; Cardiac Disease; Cardiopulmonary Bypass | terminated | 555 |
| 2025-10-07 | P2 | Bayer | NCT06149520 A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis | Thrombolysis; Symptomatic Proximal Deep Vein Thrombosis | completed | 283 |
| 2025-10-07 | P3 | Teva Pharmaceuticals USA | NCT06742957 Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | Plaque Type Psorisis | completed | 560 |
| 2025-10-07 | P2 | BioXcel Therapeutics Inc BTAIQ | NCT07116694 Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder | Bipolar I Disorder; Bipolar II Disorder; Schizophrenia; Schizoaffective Disorder; Schizophreniform D | completed | 33 |
| 2025-10-08 est. | P3 | Novartis Pharmaceuticals NVS | NCT03628053 Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | withdrawn | |
| 2025-10-08 | P1/P2 | Hoffmann-La Roche | NCT03869190 Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | Urothelial Carcinoma; Bladder Cancer | terminated | 272 |
| 2025-10-08 | P1/P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT05700084 Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 84 |
| 2025-10-08 | P2 | Lakefront Biotherapeutics NV LKFT | NCT05856448 A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | completed | 186 |
| 2025-10-08 | P3 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | NCT06142552 Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein | Severe Hemophilia A | completed | 124 |
| 2025-10-08 est. | P2 | Shin Poong Pharmaceutical Co. Ltd. | NCT06826872 Efficacy and Safety of SPC1001 in Patients With Essential Hypertension | Hypertension, Essential; Cardiovascular Diseases; Cardiology | recruiting | 252 |
| 2025-10-08 | P2 | IVIEW Therapeutics Inc. | NCT07140380 Phase 2b Controlled Study | Dry Eye Disease | completed | 30 |
| 2025-10-09 | P1/P2 | Hoffmann-La Roche | NCT03281369 A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | terminated | 219 |
| 2025-10-09 | P1/P2 | Pharmacyclics LLC. | NCT03790332 Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) | Chronic Graft Versus Host Disease | completed | 59 |
| 2025-10-09 | P3 | Hoffmann-La Roche | NCT04861259 A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic | Atypical Hemolytic Uremic Syndrome | active not recruiting | 83 |
| 2025-10-09 | P2 | AbbVie ABBV | NCT05105841 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Pa | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | completed | 20 |
| 2025-10-09 | P1/P2 | ImCheck Therapeutics, an Ipsen company | NCT05307874 Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors | Solid Tumor, Adult | terminated | 56 |
| 2025-10-09 | P2 | Sanofi SNY | NCT06028230 A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | terminated | 70 |
| 2025-10-09 | P2 | Ono Pharmaceutical Co., Ltd. | NCT06256328 A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative | Gastric Cancer | active not recruiting | 226 |
| 2025-10-09 | P3 | Boehringer Ingelheim | NCT06309992 A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohep | Obesity; Non-Alcoholic SteatoHepatitis (NASH) | completed | 218 |
| 2025-10-09 | P1/P2 | Servier Bio-Innovation LLC | NCT06563804 A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML | Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)/AML; Chronic | terminated | 13 |
| 2025-10-09 | P2 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | NCT06609460 Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications | Influenza | completed | 5071 |
| 2025-10-09 | P1/P2 | Ventus Therapeutics U.S., Inc. | NCT06822517 A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease | Parkinson Disease | terminated | 29 |
| 2025-10-10 | P2 | Zetagen Therapeutics, Inc | NCT05280067 ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES | Metastatic Breast Cancer in the Spine | completed | 10 |
| 2025-10-10 | P3 | Praxis Precision Medicines PRAX | NCT06087276 Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) | Essential Tremor | recruiting | 1000 |
| 2025-10-10 | P2/P3 | Neurocentria, Inc. | NCT06215144 Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD | Attention-Deficit/Hyperactivity Disorder (ADHD) | terminated | 95 |
| 2025-10-10 | P2 | Cardurion Pharmaceuticals, Inc. | NCT06215911 A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF) | Heart Failure; Heart Failure With Reduced Ejection Fraction; Cardiovascular Diseases; Heart Diseases | completed | 557 |
| 2025-10-11 | P1/P2 | InxMed (Shanghai) Co., Ltd. | NCT05827796 IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | Pancreatic Cancer | active not recruiting | 70 |
| 2025-10-13 | P3 | ImmunityBio, Inc. IBRX | NCT03520686 Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | terminated | 102 |
| 2025-10-13 | P1/P2 | Cullinan Therapeutics Inc. CGEM | NCT04036682 A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer; EGFR Exon 20 Mutation | active not recruiting | 284 |
| 2025-10-13 | P2 | ImmunityBio, Inc. IBRX | NCT04390399 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic | Pancreatic Cancer | active not recruiting | 328 |
| 2025-10-13 | P3 | BeiGene | NCT04486391 Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | Classical Hodgkin Lymphoma | terminated | 3 |
| 2025-10-13 | P3 | Genmab GMAB | NCT04628494 A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | active not recruiting | 483 |
| 2025-10-13 | P3 | Janssen Research & Development, LLC | NCT05572515 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed | Multiple Myeloma | active not recruiting | 614 |
| 2025-10-13 | P2 | Lakefront Biotherapeutics NV LKFT | NCT05695950 A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis | Dermatomyositis | completed | 40 |
| 2025-10-13 | P3 | Merck Sharp & Dohme LLC MRK | NCT05705349 DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) | HIV-1 Infection | active not recruiting | 537 |
| 2025-10-13 | P2 | Rose Research Center, LLC | NCT05994703 Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine | Smoking Cessation; Harm Reduction | completed | 25 |
| 2025-10-13 | P3 | Astellas Pharma Global Development, Inc. | NCT05999747 A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease | Intraoperative Ureter Visualization; Abdominolpelvic Surgery | completed | 95 |
| 2025-10-13 | P2 | Tempero Bio, Inc. | NCT06648655 A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder | Alcohol Use Disorder (AUD) | terminated | 110 |
| 2025-10-13 | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT06648772 Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study | Plaque Psoriasis | completed | 190 |
| 2025-10-13 | P3 | Taisho Pharmaceutical Co., Ltd. | NCT06745531 A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Hyperphosphatemia Patients on Hemodialysis | completed | 101 |
| 2025-10-13 | P2 | ModernaTX, Inc. | NCT06864143 A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age | Influenza; SARS-CoV-2 | completed | 1320 |
| 2025-10-13 | P3 | Genmab GMAB | NCT07226752 A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China | Diffuse Large B-Cell Lymphoma | active not recruiting | 72 |
| 2025-10-14 | P3 | Merck Sharp & Dohme LLC MRK | NCT03036488 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Parti | Triple Negative Breast Neoplasms | completed | 1174 |
| 2025-10-14 est. | P3 | Biogen BIIB | NCT03070132 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Trigeminal Neuralgia | withdrawn | |
| 2025-10-14 | P1/P2 | Hoffmann-La Roche | NCT03337698 A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | Carcinoma, Non-Small-Cell Lung | terminated | 314 |
| 2025-10-14 | P2 | Intercept Pharmaceuticals | NCT04594694 Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC | Primary Biliary Cholangitis | terminated | 75 |
| 2025-10-14 | P2 | Novartis Pharmaceuticals NVS | NCT04641442 Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP D | NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations | active not recruiting | 17 |
| 2025-10-14 | P3 | Amgen AMGN | NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junctio | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | terminated | 515 |
| 2025-10-14 | P2 | Cybin IRL Limited | NCT06051721 A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) | Generalized Anxiety Disorder | completed | 36 |
| 2025-10-14 | P3 | Colgate Palmolive CL | NCT07149376 To Assess the Efficacy of a Toothpaste Containing 8% Arginine as Compared to Colgate Cavity Protection Toothpaste in the Reduction of Dentinal Hypersensitivity. | Sensitivity, Tooth | completed | 84 |
| 2025-10-15 | P2 | Novartis Pharmaceuticals NVS | NCT03874858 A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia | Chronic Myeloid Leukemia | terminated | 135 |
| 2025-10-15 est. | P2 | Xencor, Inc. XNCR | NCT05032040 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Ovarian Cancer; Clear Cell Carcinoma; Endometrial Cancer; Cervical Carcinoma; Metastatic Castration- | active not recruiting | 170 |
| 2025-10-15 | P1/P2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | NCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | Ovarian Cancer; Platinum-resistant Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Canc | completed | 117 |
| 2025-10-15 est. | P2 | Shanghai Henlius Biotech | NCT05239650 Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC | CRC | unknown | 50 |
| 2025-10-15 | P3 | Novo Nordisk A/S NVO | NCT05726227 A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Obesity | active not recruiting | 212 |
| 2025-10-15 | P2 | Genfit | NCT05900050 Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® | Acute-On-Chronic Liver Failure; Ascites | terminated | 15 |
| 2025-10-15 est. | P3 | Suzhou Alphamab Co., Ltd. | NCT06312475 Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors | Hemophilia A With Inhibitor; Hemophilia B With Inhibitor | active not recruiting | 53 |
| 2025-10-15 | P2 | AstraZeneca AZN | NCT06435273 Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma | Asthma | completed | 36 |
| 2025-10-15 est. | P2 | Shanghai SIMR Biotechnology Co., Ltd. | NCT06577558 Efficacy and Safety of SR1375 in Adult Patients With CAP | Community-acquired Pneumonia | recruiting | 240 |
| 2025-10-15 | P2 | Regeneron Pharmaceuticals REGN | NCT06833190 REGN5381 in Adult Participants With Uncontrolled Hypertension | Uncontrolled Hypertension | terminated | 34 |
| 2025-10-15 | P3 | Laboratorios Silanes S.A. de C.V. | NCT06916884 Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine | Allergic Rhinitis | completed | 70 |
| 2025-10-15 | P3 | R-Pharm | NCT07386938 A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients W | Locally Advanced Breast Cancer; Metastatic Breast Cancer | active not recruiting | 246 |
| 2025-10-16 | P3 | Neurocrine Biosciences NBIX | NCT05206513 Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy | Dyskinesia; Cerebral Palsy | completed | 86 |
| 2025-10-16 | P1/P2 | Kineta Inc. | NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | Cancer; Solid Tumor; Melanoma; Carcinoma; Sarcoma; Lung Cancer; Prostate Cancer; Breast Cancer; Colo | completed | 40 |
| 2025-10-16 | P3 | Merck Sharp & Dohme LLC MRK | NCT05766501 A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Receiv | HIV Infection | active not recruiting | 641 |
| 2025-10-16 | P2 | argenx ARGX | NCT05907096 ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function | Delayed Graft Function | active not recruiting | 103 |
| 2025-10-16 | P2 | CatalYm GmbH | NCT06059547 Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer | Bladder Cancer; Adult Solid Tumor | completed | 31 |
| 2025-10-16 | P2 | Pacira Pharmaceuticals, Inc PCRX | NCT06977568 A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip | Osteoarthritis of Hip | terminated | 1 |
| 2025-10-17 | P2 | Sintetica SA | NCT03918798 The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population | Hernia, Inguinal; Flat Foot | completed | 164 |
| 2025-10-17 | P2 | Janssen Research & Development, LLC | NCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | Alzheimer Disease; Cognitive Dysfunction; Dementia | terminated | 523 |
| 2025-10-17 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04700072 Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metasta | Melanoma | completed | 56 |
| 2025-10-17 est. | P1/P2 | Salubris Biotherapeutics Inc | NCT05620134 Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | Cancer; Tumor, Solid; Advanced Solid Tumor; Metastatic Cancer; Melanoma; Colorectal Cancer; Non-smal | unknown | 263 |
| 2025-10-17 | P2 | Chengdu Suncadia Medicine Co., Ltd. | NCT06137768 A Trial of HRS-5965 Tablets in Primary IgA Nephropathy | Primary IgA Nephropathy | completed | 123 |
| 2025-10-17 | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06304974 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01 | Esophageal Squamous Cell Carcinoma | active not recruiting | 497 |
| 2025-10-17 | P3 | Takeda TAK | NCT06323356 A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Generalized Pustular Psoriasis; Erythrodermic Psoriasis | completed | 18 |
| 2025-10-17 | P3 | Pharvaris Netherlands B.V. PHVS | NCT06343779 Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema | Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angio | completed | 134 |
| 2025-10-17 | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06451640 A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | completed | 59 |
| 2025-10-17 | P1/P2 | Antiva Biosciences | NCT06491446 Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts | Human Papillomavirus Infection | completed | 141 |
| 2025-10-17 | P2 | Dizal Pharmaceuticals | NCT06511895 AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) | Peripheral T Cell Lymphoma | completed | 57 |
| 2025-10-18 | P2 | Eli Lilly and Company LLY | NCT06220669 A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis | Multiple Sclerosis | terminated | 65 |
| 2025-10-18 | P3 | Teikoku Seiyaku Co., Ltd. | NCT06866613 Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains. | Ankle Sprains | completed | 69 |
| 2025-10-20 | P3 | AbbVie ABBV | NCT04686136 A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine | Episodic Migraine; Chronic Migraine | completed | 596 |
| 2025-10-20 | P2/P3 | Ultragenyx Pharmaceutical Inc RARE | NCT05125809 Setrusumab vs Placebo for Osteogenesis Imperfecta | Osteogenesis Imperfecta | active not recruiting | 183 |
| 2025-10-20 | P3 | Ono Pharmaceutical Co., Ltd. | NCT05144854 A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Un | Gastric Cancer | active not recruiting | 626 |
| 2025-10-20 | P3 | ModernaTX, Inc. | NCT05436834 A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age | SARS-CoV-2 | completed | 1807 |
| 2025-10-20 | P3 | Corxel Pharmaceuticals | NCT06116968 An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM | Obstructive Hypertrophic Cardiomyopathy | completed | 40 |
| 2025-10-20 | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06554847 Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic; Eczema, Atopic | completed | 417 |
| 2025-10-20 est. | P3 | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | NCT06942793 A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients | Dry Eye Disease | not yet recruiting | 396 |
| 2025-10-21 | P2 | Sanofi SNY | NCT05156710 BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) | Transplant Rejection | active not recruiting | 48 |
| 2025-10-21 | P2/P3 | Intercept Pharmaceuticals | NCT06121375 Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Part | Biliary Atresia | terminated | 28 |
| 2025-10-21 | P3 | Intercept Pharmaceuticals | NCT06488911 To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate | Primary Biliary Cholangitis | terminated | 62 |
| 2025-10-21 | P2 | GlaxoSmithKline | NCT06663436 A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants | Diarrhoea | completed | 200 |
| 2025-10-21 | P3 | Daewon Pharmaceutical Co., Ltd. | NCT07444762 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A | Primary Hypercholesterolemia; Mixed Dyslipidemia | completed | 184 |
| 2025-10-22 | P1/P2 | Transgene | NCT04725331 A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Metastatic Cancer; Soft Tissue Sarcoma; Merkel Cell Carcinoma; Melanoma; Triple Negative Breast Canc | terminated | 31 |
| 2025-10-22 | P2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | NCT04814108 A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | Uterine Serous Carcinoma | completed | 92 |
| 2025-10-22 | P2 | Soligenix SNGX | NCT05442190 Topical SGX302 for Mild-to-Moderate Psoriasis | Psoriasis; Plaque Psoriasis; Psoriasis Vulgaris | completed | 15 |
| 2025-10-22 | P2 | Boehringer Ingelheim | NCT05559580 A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms | Scleroderma, Systemic | completed | 214 |
| 2025-10-22 | P3 | Astellas Pharma Inc | NCT06206408 A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause | Hot Flashes | completed | 410 |
| 2025-10-22 | P2 | Nido Biosciences, Inc. | NCT06411912 A Study of NIDO-361 in Patients With SBMA | Spinal and Bulbar Muscular Atrophy; Kennedy's Disease | completed | 54 |
| 2025-10-22 | P2 | Chongqing Claruvis Pharmaceutical Co., Ltd. | NCT06481475 A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines | Moderate to Severe Glabellar Lines | completed | 153 |
| 2025-10-22 est. | P3 | Hansoh BioMedical R&D Company | NCT06672393 A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis | Psoriasis | unknown | 375 |
| 2025-10-22 | P2 | The United Bio-Technology (Hengqin) Co., Ltd. | NCT07177469 UBT251 Injection Phase II Study (Overweight or Obesity) | Obesity &Amp; Overweight | completed | 205 |
| 2025-10-22 | P2 | Traditional Naturals Research Inc. | NCT07809282 A Study of Mitragynine Formulations for Exercise-Induced Muscle Soreness in Healthy Adults | Delayed Onset Muscle Soreness (DOMS); Exercise-Induced Muscle Soreness | completed | 100 |
| 2025-10-23 | P3 | Bayer | NCT05686070 A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attac | Prevention of Ischemic Stroke; Acute Non-cardioembolic Ischemic Stroke; High-risk Transient Ischemic | completed | 12327 |
| 2025-10-23 | P3 | Ultragenyx Pharmaceutical Inc RARE | NCT05768854 Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta | Osteogenesis Imperfecta | active not recruiting | 69 |
| 2025-10-23 | P2 | Sanofi SNY | NCT06058156 Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | terminated | 70 |
| 2025-10-23 | P3 | Hangzhou Highlightll Pharmaceutical Co., Ltd | NCT06396026 A Study of Efficacy and Safety of TLL-018 in CSU Participants | Chronic Spontaneous Urticaria | active not recruiting | 440 |
| 2025-10-23 | P2 | Pfizer PFE | NCT06717425 A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity | Obesity | completed | 263 |
| 2025-10-24 | P1/P2 | Sotio Biotech Inc. | NCT05120271 BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors | Hepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Myxoid/Round C | active not recruiting | 7 |
| 2025-10-24 | P2/P3 | Alume Biosciences, Inc. | NCT06227585 Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery | Head and Neck Surgery | completed | 155 |
| 2025-10-24 | P2 | Bayer | NCT06522997 A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease | Chronic Kidney Disease | completed | 1222 |
| 2025-10-24 | P2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | NCT06693843 A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight | Obesity, Overweight, or Chronic Weight Management | completed | 230 |
| 2025-10-25 est. | P3 | Akeso | NCT06371157 A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular | Hepatocellular Carcinoma | recruiting | 469 |
| 2025-10-26 | P2 | Xiamen Amoytop Biotech Co., Ltd. | NCT06552429 Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET | Essential Thrombocythemia | recruiting | 27 |
| 2025-10-27 | P3 | Biohaven Pharmaceuticals, Inc. BHVN | NCT04641143 Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder | Obsessive-Compulsive Disorder | completed | 456 |
| 2025-10-27 | P3 | Merck Sharp & Dohme LLC MRK | NCT04700124 Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) | Bladder Cancer | active not recruiting | 808 |
| 2025-10-27 | P2 | GlaxoSmithKline | NCT04880031 A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension | Nonalcoholic Steatohepatitis (NASH) | completed | 231 |
| 2025-10-27 | P3 | Alume Biosciences, Inc. | NCT05377554 Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery | Surgery | completed | 154 |
| 2025-10-27 | P1/P2 | Antiva Biosciences | NCT05502367 A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia | Cervical Intraepithelial Neoplasia | terminated | 44 |
| 2025-10-27 | P1/P2 | AnaCardio AB | NCT05642507 Phase Ib/IIa Trial With AC01 in Patients With HFrEF | Heart Failure With Reduced Ejection Fraction | completed | 58 |
| 2025-10-27 | P2 | TBF Genie Tissulaire | NCT06034262 Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis | Osteoarthritis Hand | terminated | 1 |
| 2025-10-27 | P2 | Diasome Pharmaceuticals | NCT06238778 Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec | Diabetes Mellitus, Type 1 | completed | 227 |
| 2025-10-27 | P3 | Gilead Sciences GILD | NCT06333808 Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy | HIV-1-infection | active not recruiting | 577 |
| 2025-10-28 | P3 | GlaxoSmithKline | NCT04965636 Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) | Hypereosinophilic Syndrome | completed | 16 |
| 2025-10-28 | P3 | Takeda TAK | NCT05084053 A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP); Multifocal Motor Neuropathy (MMN) | completed | 26 |
| 2025-10-28 | P2 | Intra-Cellular Therapies, Inc. | NCT05766813 Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease | Parkinson Disease | completed | 79 |
| 2025-10-28 est. | P3 | Mezzion Pharma Co. Ltd | NCT05918211 Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Single Ventricle Heart Disease | recruiting | 436 |
| 2025-10-28 | P2 | AstraZeneca AZN | NCT06020014 Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA | Asthma | completed | 339 |
| 2025-10-28 | P2 | NMD Pharma A/S | NCT06482437 Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease | Charcot-Marie-Tooth Disease | completed | 81 |
| 2025-10-28 | P2 | Chong Kun Dang Pharmaceutical | NCT06954766 Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981 | Knee Osteoarthritis | completed | 100 |
| 2025-10-30 | P3 | Amgen AMGN | NCT04175613 A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis | Psoriasis | completed | 160 |
| 2025-10-30 | P1/P2 | NETRIS Pharma | NCT04652076 GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab | Endometrial Carcinoma; Cervix Carcinoma | active not recruiting | 240 |
| 2025-10-30 | P2 | ITB-Med LLC | NCT04803006 A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA) | Kidney Transplantation | terminated | 4 |
| 2025-10-30 | P1/P2 | CanariaBio Inc. | NCT04938583 Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | Ovarian Cancer by FIGO Stage; Ovarian Cancer Stage III; Ovarian Cancer Stage IV | active not recruiting | 54 |
| 2025-10-30 | P2/P3 | Agios Pharmaceuticals, Inc. AGIO | NCT05031780 A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | Sickle Cell Disease | active not recruiting | 286 |
| 2025-10-30 est. | P1/P2 | Beijing Konruns Pharmaceutical Co., Ltd. | NCT05260385 To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors | Digestive System Tumors | unknown | 133 |
| 2025-10-30 est. | P2 | Shanghai Kechow Pharma, Inc. | NCT05331105 HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | Neurofibromatosis 1; Plexiform Neurofibromas | recruiting | 70 |
| 2025-10-30 | P3 | Takeda TAK | NCT05513586 A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants | Primary Immunodeficiency Diseases (PID) | completed | 15 |
| 2025-10-30 est. | P2 | FAScinate Therapeutics Inc. | NCT05670782 A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease | Parkinson Disease | unknown | 314 |
| 2025-10-30 | P2 | Technophage, SA | NCT05948592 Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection | Diabetic Foot Infection | completed | 76 |
| 2025-10-30 est. | P2 | Keymed Biosciences Co.Ltd | NCT06525597 Study of Stapokibart Injection in Patients With Allergic Rhinitis | Allergic Rhinitis | unknown | 120 |
| 2025-10-30 est. | P2 | Hansoh BioMedical R&D Company | NCT06594965 A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | Myelodysplastic Syndromes; Anemia; MDS; Bone Marrow Disease | unknown | 176 |
| 2025-10-30 | P2 | Shanghai Bovax Biotechnology Co., Ltd. | NCT06756269 To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years | HPV Infection; HPV-Related Carcinoma; HPV-Related Intraepithelial Neoplasia; Genital Wart | recruiting | 330 |
| 2025-10-30 est. | P2 | Alphyn Biologics | NCT06855745 Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. | Atopic Dermatitis (Eczema); Atopic Dermatitis Eczema; Atopic Dermatitis; Atopic Dermatitis (AD); Ecz | recruiting | 72 |
| 2025-10-30 | P3 | Laboratorios Silanes S.A. de C.V. | NCT06863636 Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation | Joint Pain; Knee Osteoarthritis; Hip Osteoarthritis | completed | 231 |
| 2025-10-30 est. | P2 | Zhejiang Wenda Pharma Technology LTD. | NCT06912165 A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis | Brief Description of Focus of Study | recruiting | 140 |
| 2025-10-31 | P2 | Merck Sharp & Dohme LLC MRK | NCT04165083 KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-pr | Carcinoma, Non-Small-Cell Lung | completed | 100 |
| 2025-10-31 est. | P1/P2 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | NCT04632108 A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Soli | Malignant Solid Tumor | active not recruiting | 199 |
| 2025-10-31 | P3 | Chiesi Farmaceutici S.p.A. | NCT04636801 A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subje | Chronic Obstructive Pulmonary Disease | terminated | 4710 |
| 2025-10-31 | P1/P2 | GeoVax, Inc. GOVX | NCT04639466 A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection | COVID-19 Infection | completed | 119 |
| 2025-10-31 | P2 | Bristol-Myers Squibb BMY | NCT05413018 An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission | Leukemia, Myeloid, Acute | active not recruiting | 34 |
| 2025-10-31 est. | P1/P2 | AskGene Pharma, Inc. | NCT05632939 ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. | Gastric Cancer; Gastroesophageal Cancer (GC) | active not recruiting | 62 |
| 2025-10-31 est. | P2 | CellSight Technologies, Inc. | NCT06084806 Test-retest Evaluation of [18F]F-AraG PET | Non-small Cell Lung Cancer | unknown | 10 |
| 2025-10-31 | P1/P2 | AstraZeneca AZN | NCT06179511 Study of AZD9829 in CD123+ Hematological Malignancies | Hematological Malignancies | completed | 56 |
| 2025-10-31 | P2 | Cybrexa Therapeutics | NCT06315491 A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Platinum-resistant Ovarian Cancer; Refractory Ovarian Carcinoma | terminated | 40 |
| 2025-10-31 | P3 | VistaGen Therapeutics, Inc. VTGN | NCT06358651 Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) | Social Anxiety Disorder | completed | 238 |
| 2025-10-31 est. | P1/P2 | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. | NCT06649708 HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies | Advanced Solid Tumor Malignancies | recruiting | 100 |
| 2025-10-31 | P1/P2 | Korro Bio, Inc. KRRO | NCT06677307 A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 | Alpha-1 Anti-trypsin Deficiency; AATD | terminated | 42 |
| 2025-10-31 est. | P1/P2 | PT Bio Farma | NCT06690515 Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants | Vaccine Adverse Reaction; Vaccine Reaction | unknown | 465 |
| 2025-10-31 est. | P1/P2 | Luye Pharma Group Ltd. | NCT06731868 Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia | Tardive Dyskinesia (TD) | recruiting | 120 |
| 2025-10-31 est. | P1/P2 | Huabo Biopharm Co., Ltd. | NCT06758557 A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | Advanced NSCLC; Advanced Endometrial Cancer | recruiting | 282 |
| 2025-10-31 | P2 | Jiangsu vcare pharmaceutical technology co., LTD | NCT06891040 Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis | Atopic Dermatitis | completed | 118 |
| 2025-10-31 | P1/P2 | Haihe Biopharma Co., Ltd. | NCT06909877 Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | recruiting | 100 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.